UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of December 2017

Commission File Number: 001-38281

 

 

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

 

 

Bâtiment Adénine, 60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒  Form 20-F            ☐  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

---

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

ERYTECH Pharma S.A. is submitting this Report on Form 6-K to furnish its (i) unaudited interim condensed consolidated statements of financial position as of December 31, 2016 and June 30, 2017 and (ii) unaudited interim condensed consolidated statements of income (loss) for the six months ended June 30, 2016 and 2017, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K.

---

EXHIBIT LIST

 

Exhibit		Description
99.1		Unaudited Interim Condensed Consolidated Statements of Financial Position as of December 31, 2016 and June 30, 2017
99.2		Unaudited Interim Condensed Consolidated Statements of Income (Loss) for the Six Months Ended June 30, 2016 and 2017

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

				ERYTECH Pharma S.A.
Date: December 7, 2017				By:		/s/ Eric Soyer
						Name   Eric Soyer
						Title:    Chief Financial Officer and Chief Operating Officer

Exhibit 99.1

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Amounts in thousands of euros)

 

		As of
		December 31, 2016				June 30, 2017
		€				€
ASSETS
Non-current assets
Intangible assets			57				43
Property, plant and equipment, net			2,245				2,730
Other non-current financial assets			132				130
Total non-current assets			2,434				2,903
Current assets
Inventories			145				170
Trade and other receivables			218				336
Other current assets			4,524				7,348
Cash and cash equivalents			37,646				88,551
Total current assets			42,533				96,405
TOTAL ASSETS			44,967				99,307
		As of
		December 31, 2016				June 30, 2017
		€				€
LIABILITIES AND SHAREHOLDERS’ EQUITY
Shareholders’ equity
Share capital			873				1,174
Premiums related to share capital			105,090				170,159
Reserves			(48,412	)			(69,581	)
Net loss for the period			(21,913	)			(14,081	)
Total shareholders’ equity			35,638				87,671
Non-current liabilities
Long-term provisions			163				167
Financial liabilities—non-current portion			2,816				2,426
Deferred tax			3				3
Total non-current liabilities			2,982				2,596
Current liabilities
Financial liabilities—current portion			50				817
Trade and other payables			4,832				6,164
Other current liabilities			1,465				2,059
Total current liabilities			6,347				9,040
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY			44,967				99,307

Exhibit 99.2

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(Amounts in thousands of euros, except per share amounts)

 

		Six Months Ended June 30,
		2016				2017
		€				€
Operating income
Revenues
Other income			2,403				1,788
Total operating income			2,403				1,788
Operating expenses
Research and development			(8,800	)			(12,082	)
General and administrative			(4,222	)			(3,895	)
Total operating expenses			(13,022	)			(15,977	)
Operating loss			(10,618	)			(14,189	)
Financial income			292				160
Financial expenses			(32	)			(47	)
Financial income			260				113
Income tax			9				(5	)
Net loss			(10,349	)			(14,081	)
Basic / diluted loss per share (€/share)			(1.31	)			(1.42	)